Our strategy is to use novel technologies to develop monoclonal antibodies (mAbs) to innovative and therapeutic targets in oncology and autoimmune disease. Our in-house mAb pipeline maximises our technology’s application in the development of novel medicines.


The company has a highly experienced leadership team and Board of Directors whom have proven track records of successfully developing marketed therapeutic biologics and growing multimillion dollar companies.

Our Mission

Founded in 2014, Capella BioScience raised £1.5M of equity financing from Advent Life sciences and Index ventures. This enables our mission to advance our pipeline of first-in-class mAb therapeutics in areas of high unmet medical need.

Capella BioScience. Developing innovative mAbs.

We are developing a strong portfolio of mAbs in oncology and autoimmune disease.